{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:31:48Z","timestamp":1781659908896,"version":"3.54.5"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.clgc.2016.10.004","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T00:45:15Z","timestamp":1476924315000},"page":"280-290.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Therapy of Treatment-Related Hypertension in Metastatic Renal-Cell Cancer Patients Receiving Sunitinib"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2862-7302","authenticated-orcid":false,"given":"Philipp","family":"Ivanyi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gernot","family":"Beutel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Drewes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Pirr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan T.","family":"Kielstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2016.10.004_bib1","first-page":"232","article-title":"Novel therapies in advanced renal cell carcinoma: management of adverse events from sorafenib and sunitinib","volume":"105","author":"Ivanyi","year":"2008","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.clgc.2016.10.004_bib2","first-page":"129","article-title":"Molecular targeted therapies for solid tumors: management of side effects","volume":"32","author":"Grunwald","year":"2009","journal-title":"Onkologie"},{"key":"10.1016\/j.clgc.2016.10.004_bib3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.10.004_bib4","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.ejca.2011.03.033","article-title":"The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer","volume":"47","author":"Bamias","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2016.10.004_bib5","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdp025","article-title":"Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis","volume":"20","author":"Di Lorenzo","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.10.004_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/02841860802314720","article-title":"Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis","volume":"48","author":"Zhu","year":"2009","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clgc.2016.10.004_bib7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/annonc\/mdq357","article-title":"A\u00a0phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group study","volume":"22","author":"Biagi","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.10.004_bib8","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/annonc\/mdn713","article-title":"Management of hypertension in angiogenesis inhibitor-treated patients","volume":"20","author":"Izzedine","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.10.004_bib9","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/ncpcardio1375","article-title":"Vascular complications of selected cancer therapies","volume":"5","author":"Daher","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.clgc.2016.10.004_bib10","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.eururo.2007.08.053","article-title":"High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor","volume":"53","author":"Pouessel","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2016.10.004_bib11","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.10.004_bib12","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2016.10.004_bib13","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","article-title":"Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma","volume":"26","author":"Schmidinger","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.10.004_bib14","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.eururo.2015.04.017","article-title":"SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer","volume":"68","author":"Eichelberg","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2016.10.004_bib15","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1200\/JCO.2008.21.6028","article-title":"Could rigorous diagnosis and management of hypertension reduce cardiac events in patients with renal cell carcinoma treated with tyrosine kinase inhibitors?","volume":"27","author":"Bamias","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.10.004_bib16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jchf.2012.09.001","article-title":"The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients","volume":"1","author":"Hall","year":"2013","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.clgc.2016.10.004_bib17","first-page":"4057","article-title":"Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents","volume":"24","author":"Escalante","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clgc.2016.10.004_bib18","first-page":"405","article-title":"Confusion of therapeutic approaches","volume":"111","author":"Ivanyi","year":"2014","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.clgc.2016.10.004_bib19","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1001\/jama.291.20.2441","article-title":"Prognostic importance of comorbidity in a hospital-based cancer registry","volume":"291","author":"Piccirillo","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.clgc.2016.10.004_bib20","first-page":"41","article-title":"Cancer, comorbidities, and health-related quality of life of older adults","volume":"29","author":"Smith","year":"2008","journal-title":"Health Care Financ Rev"},{"key":"10.1016\/j.clgc.2016.10.004_bib21","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and\u00a0management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2016.10.004_bib22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1161\/HYPERTENSIONAHA.112.196774","article-title":"Management of antiangiogenic therapy\u2013induced hypertension","volume":"60","author":"de Jesus-Gonzalez","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.clgc.2016.10.004_bib23","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.clgc.2016.10.004_bib24","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0272-6386(97)90199-2","article-title":"Dialysate sodium delivery can alter chronic blood pressure management","volume":"29","author":"Flanigan","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clgc.2016.10.004_bib25","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","article-title":"Competing risk analysis using R: an easy guide for clinicians","volume":"40","author":"Scrucca","year":"2007","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.clgc.2016.10.004_bib26","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/bmt.2009.359","article-title":"Regression modeling of competing risk using R: an in depth guide for clinicians","volume":"45","author":"Scrucca","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clgc.2016.10.004_bib27","first-page":"151","article-title":"An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition","volume":"10","author":"Copur","year":"2011","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clgc.2016.10.004_bib28","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.110.992230","article-title":"Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension","volume":"124","author":"Nazer","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.clgc.2016.10.004_bib29","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00228-010-0815-4","article-title":"Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis","volume":"66","author":"An","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clgc.2016.10.004_bib30","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1093\/annonc\/mds179","article-title":"Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib","volume":"23","author":"George","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.10.004_bib31","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/cncr.28972","article-title":"Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway","volume":"121","author":"Hamnvik","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2016.10.004_bib32","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2016.10.004_bib33","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc072330","article-title":"Home blood-pressure monitoring in patients receiving sunitinib","volume":"358","author":"Azizi","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.10.004_bib34","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1158\/1078-0432.CCR-09-0058","article-title":"Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment","volume":"15","author":"Maitland","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2016.10.004_bib35","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3747\/co.19.972","article-title":"Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents","volume":"19","author":"Larochelle","year":"2012","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clgc.2016.10.004_bib36","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejca.2015.10.006","article-title":"Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced\/metastatic renal cell carcinoma?","volume":"53","author":"Goldstein","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2016.10.004_bib37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.critrevonc.2008.01.013","article-title":"The changing prevalence of comorbidity across the age spectrum","volume":"67","author":"Piccirillo","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clgc.2016.10.004_bib38","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/1078155214530177","article-title":"Claims analysis of hypertension occurrence, severity changes and patterns of antihypertensive use in cancer patients receiving vascular endothelial growth factor inhibitors","volume":"21","author":"Thompson","year":"2015","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.clgc.2016.10.004_bib39","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/cncr.26338","article-title":"Statin use and the risk of renal cell carcinoma in 2 prospective US cohorts","volume":"118","author":"Liu","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2016.10.004_bib40","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrurol.2010.46","article-title":"Epidemiology and risk factors for kidney cancer","volume":"7","author":"Chow","year":"2010","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.clgc.2016.10.004_bib41","first-page":"3465","article-title":"Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab","volume":"27","author":"Pande","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clgc.2016.10.004_bib42","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1158\/1078-0432.CCR-07-4783","article-title":"Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy","volume":"14","author":"Curwen","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2016.10.004_bib43","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s10637-010-9549-5","article-title":"Treatment of bevacizumab-induced hypertension by amlodipine","volume":"30","author":"Mir","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clgc.2016.10.004_bib44","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1200\/JCO.2009.22.2273","article-title":"Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors","volume":"27","author":"Langenberg","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.10.004_bib45","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1161\/HYPERTENSIONAHA.114.04187","article-title":"Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study","volume":"64","author":"Lankhorst","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.clgc.2016.10.004_bib46","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/annonc\/mdv147","article-title":"Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma","volume":"26","author":"Izzedine","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.10.004_bib47","first-page":"221","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review","volume":"23","author":"McMenamin","year":"2012","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.clgc.2016.10.004_bib48","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/j.ejca.2011.04.019","article-title":"Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination","volume":"47","author":"Keizman","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2016.10.004_bib49","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1158\/1078-0432.CCR-14-2332","article-title":"Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma","volume":"21","author":"McKay","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2016.10.004_bib50","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/ijc.29972","article-title":"Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: a pooled secondary analysis of clinical trials","volume":"138","author":"Sorich","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clgc.2016.10.004_bib51","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/JCO.2011.37.1195","article-title":"Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors","volume":"30","author":"Schutz","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.10.004_bib52","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.10.004_bib53","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.10.004_bib54","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.ejca.2014.05.013","article-title":"Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events","volume":"50","author":"Ewer","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2016.10.004_bib55","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/S0140-6736(00)02039-0","article-title":"Subgroup analysis and other (mis)uses of baseline data in clinical trials","volume":"355","author":"Assmann","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2016.10.004_bib56","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/annonc\/mdv103","article-title":"Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma","volume":"26","author":"Rini","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.10.004_bib57","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/bmj.38121.684410.AE","article-title":"Blood pressure control by home monitoring: meta-analysis of randomised trials","volume":"329","author":"Cappuccio","year":"2004","journal-title":"BMJ"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316303135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316303135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:27:27Z","timestamp":1761564447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767316303135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1558767316303135"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2016.10.004","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy of Treatment-Related Hypertension in Metastatic Renal-Cell Cancer Patients Receiving Sunitinib","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2016.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}